Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of LYB002V14 COVID-19 Booster Vaccine
NCT06167915Phase 1Not yet recruiting
- Sponsor
- Patronus Biotech
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LYB002V14A in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Patronus Biotech. Primary endpoint: Adverse events and adverse reactions. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
LYB002V14A
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06167915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06167915.